Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected.
-
As Alphabet follows Meta with a dividend, the pressure is now on Amazon
Dividends are a sign of maturing companies, but may also be a diversion for investors amid hefty capital spending
-
Jamie Dimon thinks the odds of a ‘soft landing’ are about half of what Wall Street expects
The JPMorgan Chase CEO’s Wall Street Journal interview covered a range of topics — from his morning routine to his views on the Fed.